NMRA
Neumora
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NMRA
Neumora Therapeutics, Inc.
A biopharmaceutical company that develops drugs for brain diseases
490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472
--
Neumora Therapeutics, Inc., was founded in November 2019 as a Delaware corporation under the name RBNC Therapeutics, Inc. The company changed its name to Neumora Therapeutics, Inc., in October 2021. The company is a clinical-stage biopharmaceutical company that takes a fundamentally different approach to the treatment of brain diseases in response to the global brain disease crisis. The company's rapidly expanding therapeutic pipeline now includes seven clinical and preclinical neuroscience programs targeting a wide range of underserved neuropsychiatric and neurodegenerative diseases with new mechanisms of action. The company's most advanced product candidate, navacaprant (NMRA-140), is a new once-daily oral kappa opioid receptor (KOR) antagonist being developed for the treatment of major depression disorder (MDD), which the company believes has the potential to provide significant advantages over standard of care if approved.
Company Financials
EPS
NMRA has released its 2024 Q4 earnings. EPS was reported at -0.37, versus the expected -0.44, beating expectations. The chart below visualizes how NMRA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
